Department of Infectious Diseases, Laboratory of Clinical Microbiology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Merck & Co., Inc, Kenilworth, NJ, USA.
BMC Infect Dis. 2020 Mar 27;20(1):250. doi: 10.1186/s12879-020-04973-0.
Treatment of resistant Pseudomonas aeruginosa infection continues to be a challenge in Latin American countries (LATAM). We synthesize the literature on the use of appropriate initial antibiotic therapy (AIAT) and inappropriate initial antibiotic therapy (IIAT) in P. aeruginosa infections, and the literature on risk factors for acquisition of resistant P. aeruginosa among hospitalized adult patients in LATAM.
MEDLINE, EMBASE, Cochrane, and LILAC were searched between 2000 and August 2019. Abstracts and full-text articles were screened in duplicate. Random effects meta-analysis was conducted when studies were sufficiently similar.
The screening of 165 citations identified through literature search yielded 98 full-text articles that were retrieved and assessed for eligibility, and 19 articles conducted in Brazil (14 articles), Colombia (4 articles), and Cuba (1 article) met the inclusion criteria. Of 19 eligible articles, six articles (840 subjects) examined AIAT compared to IIAT in P. aeruginosa infections; 17 articles (3203 total subjects) examined risk factors for acquisition of resistant P. aeruginosa; and four articles evaluated both. Four of 19 articles were rated low risk of bias and the remaining were deemed unclear or high risk of bias. In meta-analysis, AIAT was associated with lower mortality for P. aeruginosa infections (unadjusted summary OR 0.48, 95% CI 0.28-0.81; I = 59%), compared to IIAT and the association with mortality persisted in subgroup meta-analysis by low risk of bias (3 articles; unadjusted summary OR 0.46, 95% CI 0.28-0.81; I = 0%). No meta-analysis was performed for studies evaluating risk factors for acquisition of resistant P. aeruginosa as they were not sufficiently similar. Significant risk factors for acquisition of resistant P. aeruginosa included: prior use of antibiotics (11 articles), stay in the intensive care unit (ICU) (3 articles), and comorbidity score (3 articles). Outcomes were graded to be of low strength of evidence owing to unclear or high risk of bias and imprecise estimates.
Our study highlights the association of AIAT with lower mortality and prior use of antibiotics significantly predicts acquiring resistant P. aeruginosa infections. This review reinforces the need for rigorous and structured antimicrobial stewardship programs in the LATAM region.
拉丁美洲国家(LATAM)治疗耐药铜绿假单胞菌感染仍然是一个挑战。我们综合了有关铜绿假单胞菌感染中适当初始抗生素治疗(AIAT)和不适当初始抗生素治疗(IIAT)的文献,以及 LATAM 住院成年患者获得耐药铜绿假单胞菌的危险因素的文献。
2000 年至 2019 年 8 月期间,我们在 MEDLINE、EMBASE、Cochrane 和 LILAC 上进行了检索。对摘要和全文文章进行了重复筛选。当研究足够相似时,进行了随机效应荟萃分析。
通过文献检索筛选出的 165 条引文,共检索出 98 篇全文文章进行了资格评估,其中 19 篇文章符合纳入标准,这些文章来自巴西(14 篇)、哥伦比亚(4 篇)和古巴(1 篇)。在 19 篇合格文章中,有 6 篇(840 名受试者)研究了 AIAT 与铜绿假单胞菌感染中的 IIAT 相比;17 篇(3203 名受试者)文章研究了获得耐药铜绿假单胞菌的危险因素;4 篇文章同时评估了两者。19 篇文章中有 4 篇被评为低偏倚风险,其余被评为不确定或高偏倚风险。荟萃分析显示,与 IIAT 相比,AIAT 与铜绿假单胞菌感染的死亡率较低相关(未调整的汇总 OR 0.48,95%CI 0.28-0.81;I=59%),且在低偏倚风险的亚组荟萃分析中,这种关联仍存在(3 篇文章;未调整的汇总 OR 0.46,95%CI 0.28-0.81;I=0%)。没有进行评估获得耐药铜绿假单胞菌的危险因素的研究的荟萃分析,因为它们不够相似。获得耐药铜绿假单胞菌的显著危险因素包括:既往使用抗生素(11 篇文章)、入住重症监护病房(ICU)(3 篇文章)和合并症评分(3 篇文章)。由于存在不明确或高偏倚风险以及估计不精确,结果被评为证据强度低。
我们的研究强调了 AIAT 与较低死亡率的相关性,并且既往使用抗生素显著预测了耐药铜绿假单胞菌感染的发生。这篇综述强调了在 LATAM 地区需要严格和结构化的抗菌药物管理计划。